While non-response to Dupixent is uncommon, atopic dermatitis (AD) patients who are refractory lack safe and effective treatments.

NEWTON, Mass., July 26, 2023 /PRNewswire/ — Atopic dermatitis (AD) is a chronic, inflammatory skin disease characterized by skin lesions and severe itching.

Dermatologists typically begin AD treatment with topical corticosteroids, then progress to Dupixent for uncontrolled, moderate-severe cases. For patients who are refractory to Dupixent (9% of moderate cases and 16% of severe cases), physicians turn to oral JAK inhibitors despite associated black box warnings, according to REACH Market Research. Adbry, an IL-13 with a similar mechanism of action to Dupixent, was approved in late 2021, however, interviewed dermatologists report that in their experience Adbry is not as effective as Dupixent.

These post-Dupixent AD therapy options include:

  • LEO Pharma’s IL-13 inhibitor Adbry (tralokinumab)
  • Pfizer’s JAK inhibitor Cibinqo (abrocitinib)
  • AbbVie’s JAK inhibitor Rinvoq (upadacitinib)

To access REACH’s MarketVue® Report on Dupixent-refractory AD, visit https://reachmr.com or contact us at info@reachmr.com.

The AD pipeline is full of promising new biologics in development, including:

  • Eli Lilly’s IL-13 inhibitor lebrikizumab
  • Keymed’s IL-4Rα inhibitor CM310
  • Galderma’s IL-31R inhibitor nemolizumab
  • Amgen/Kyowa’s OX40 inhibitor rocatinlimab

Most therapies in development for AD target patients with inadequate response to topicals rather than Dupixent-refractory patients, however, Eli Lilly’s lebrikizumab is one of the few investigational therapies specifically being studied in Dupixent-refractory patients.

Dermatologist, U.S.: Lebrikizumab is coming. I think of it as a lot like Dupixent, so if somebody failed Dupixent, lebrikizumab might be a really good choice. And then Galderma’s nemolizumab, I think the indication would probably be itch in people with atopic dermatitis. That I think is going to do well, but I don’t think it’s going to take away sales from Dupixent.

 

About MarketVue®

MarketVue® reports are a rare disease focused, fresh alternative to traditionally long and outdated market research reports. MarketVue® reports cover rare disease epidemiology and key market dynamics based on research from key opinion leader interviews, physician surveys, and secondary data.